OBJECTIVE: To evaluate the ability of commercial, chromogenic kits designed to measure human fibrinolytic pathway components to measure the canine plasma fibrinolytic pathway enzymes, tissue plasminogen activator (tPA) and plasminogen (PLG), and their respective inhibitors, plasminogen activator inhibitor 1 (PAI) and alpha 2-antiplasmin (AP). ANIMALS: 20 healthy dogs of various ages and breeds. PROCEDURE: The commercial procedure was adapted to a microtitration plate. Standard curves were generated by use of a canine plasma pool. RESULTS: Modifications of the commercial kit consisted of change in incubation periods and the substitution of urokinase for the streptokinase. Plasminogen and AP procedures yielded intra- and interassay coefficients of variation (CV) ranging from 2 to 6.4%. The tPA activity gave an acceptable intra-assay CV of 4.2%, but an equivocal interassay CV of 18%. The PAI assay gave unacceptable intra-assay and interassay CV of 59 and 66%, respectively. CONCLUSIONS: Modifications of the commercial PLG and AP procedures were appropriate for use with fresh and frozen canine plasma. However, equivocal results were obtained for canine plasma tPA. Although the PAI assay was able to detect the inhibitor, it gave unacceptable quantifiable results. Human and canine plasma contained similar amounts of PLG and AP, but 25% more tPA was found in canine plasma than human plasma. CLINICAL RELEVANCE: With modifications, the commercial human PLG and AP chromogenic kits may serve to elucidate such canine fibrinolytic disorders as disseminated coagulopathy. The high cost of the chromogenic substrate limits its application.
OBJECTIVE: To evaluate the ability of commercial, chromogenic kits designed to measure human fibrinolytic pathway components to measure the canine plasma fibrinolytic pathway enzymes, tissue plasminogen activator (tPA) and plasminogen (PLG), and their respective inhibitors, plasminogen activator inhibitor 1 (PAI) and alpha 2-antiplasmin (AP). ANIMALS: 20 healthy dogs of various ages and breeds. PROCEDURE: The commercial procedure was adapted to a microtitration plate. Standard curves were generated by use of a canine plasma pool. RESULTS: Modifications of the commercial kit consisted of change in incubation periods and the substitution of urokinase for the streptokinase. Plasminogen and AP procedures yielded intra- and interassay coefficients of variation (CV) ranging from 2 to 6.4%. The tPA activity gave an acceptable intra-assay CV of 4.2%, but an equivocal interassay CV of 18%. The PAI assay gave unacceptable intra-assay and interassay CV of 59 and 66%, respectively. CONCLUSIONS: Modifications of the commercial PLG and AP procedures were appropriate for use with fresh and frozen canine plasma. However, equivocal results were obtained for canine plasma tPA. Although the PAI assay was able to detect the inhibitor, it gave unacceptable quantifiable results. Human and canine plasma contained similar amounts of PLG and AP, but 25% more tPA was found in canine plasma than human plasma. CLINICAL RELEVANCE: With modifications, the commercial humanPLG and AP chromogenic kits may serve to elucidate such caninefibrinolytic disorders as disseminated coagulopathy. The high cost of the chromogenic substrate limits its application.
Authors: Stuart Ainsworth; Stuart Carter; Claire Fisher; Jenna Dawson; Loria Makrides; Tim Nuttall; Sarah L Mason Journal: Anim Genet Date: 2015-09-11 Impact factor: 3.169